0
0
Subtotal: $0.00
No products in the cart.

To make a purchase using a Purchase Order, please contact us.

TumorGenesis® Normal or Transformed Ovary and Fallopian Tube Media (Ince FOMI) (Liquid)

Product No:
839

Normal or Transformed Ovary and Fallopian Tube Media (Ince)

Suggested Usage
NORMAL IMMORTALIZED OVARY CELL LINES Immortalized with hTERT-pgp OCE1 Ovarian Surface OCE2 Ovarian Surface
TRANSFORMED OVARY CELL LINES Transformed with hTERT-gfp + LT/st OCLE1 Ovarian Surface OCLE2 Ovarian Surface
TUMORIGENIC OVARY CELL LINES Transformed with hTERT-gfp + LT/st + H-Ras OCLER1 Ovarian Surface OCLER2 Ovarian Surface
NORMAL IMMORTALIZED FALLOPIAN TUBE CELL LINES Immortalized with hTERT-pgp FNE1 Fallopian Non-ciliated FNE2 Fallopian Non-ciliated
TRANSFORMED FALLOPIAN TUBE CELL LINES Transformed with hTERT-gfp + LT/st FNLE1 Fallopian Non-ciliated FNLE2 Fallopian Non-ciliated
TUMORIGENIC FALLOPIAN TUBE CELL LINES Transformed with hTERT-gfp + LT/st + H-Ras FNLER1 Fallopian Non-ciliated FNLER2 Fallopian Non-ciliated
Tan A. Ince, MD, PhD – Fighting Cancer by Keeping Cancer Cells Alive
Feb 12, 2017 – Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.
Customer supplied
To be supplemented with 0-2% fetal bovine serum to media To be supplemented with Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.
Appearance
Red, clear, complete
FOMI Bullet 1 Included (506388B, Colorless) Supplied as a liquid. Vortex, spin down and add whole vial to 506388.
Storage (506388B)
Liquid is stable at 4°C.
FOMI Bullet 2 Included (506388C, Pink) Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388.
Storage (506388C)
Liquid is stable at -20°C
Storage and Stability w/o supplements)
Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.
(w/ supplements)
Storage and Stability Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.
Storage (506388B)
Liquid is stable at 4°C.
Storage (506388C)
Liquid is stable at -20°C.
Country of Origin United States
FOMI Bullet Included (506388B)
Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388.
Storage (506388B)
Vial is stable at -20°C. Once thawed and added to 506388, the complete media is stable for 6 weeks at 4°C when stored in the dark.
Important Note
Cholera toxin is NOT included in the liquid media nor the bullet. Shipping regulations have made it increasingly difficult to ship. Please procure from your local supplier. Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.
Licensed by TumorGenesis®. Manufactured for research use by US Biological.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards
All products should be handled by qualified personnel only, trained in laboratory procedures.

Purchase

Product No. Size Price
839 $579.00

Related Information

Supporting
Data

Related
Products

Product
Usage

Protocols

References

Supporting Data

Reactivity
Sensitivity
MW (kDa)
Source/Isotype
Application Key:

WB-Western Blot IP-Immunoprecipitation IHC-Immunohistochemistry ChIP-Chromatin Immunoprecipitation IF-Immunofluorescence F-Flow Cytometry E-P-ELISA-Peptide

 

Species Cross-Reactivity Key:
H-Human M-Mouse R-Rat Hm-Hamster Mk-Monkey Vir-Virus Mi-Mink C-Chicken Dm-D. melanogaster X-Xenopus Z-Zebrafish B-Bovine Dg-Dog Pg-Pig Sc-S. cerevisiae Ce-C. elegans Hr-Horse All-All Species Expected

 

Related Products

Related products

Applications -

Researches -

Product categories +

# Product Name Application Category
838 TumorGenesis® Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince OCMI-Le) (Liquid)
  • WP
  • IP
  • IHC
  • IF
837 TumorGenesis® Primary Ovarian Cancer Establishment Media (Ince OCMI-e) (Liquid)
  • WP
  • IP
835 TumorGenesis® Primary Ovarian Cancer Maintenance Media (Ince OCMI-L) (Liquid)
  • WP
  • IHC
  • IF
  • ChIP
833 TumorGenesis® Transformed Breast Media (Ince BMI-T) (Liquid)
  • WP
  • IHC
  • F

Product Usage

Protocols

Specificity / Sensitivity
Source / Purification

References

Database Links

Purchase

Product No. Size Price
839 $579.00

Lawrence J. DeLucas, PhD

VP, OPERATIONS,
Predictive Oncology
Site Leader, Soluble Biotech
At Predictive Oncology

Dr. DeLucas is the Vice president of Operations for Predictive Oncology and President and co-founder of Soluble Biotech, Inc. DeLucas is currently working to complete development of GMP facilities at Soluble Biotech and at TumorGenesis. In addition, he oversees Soluble Biotech’s solubility and stability contracts for numerous pharmaceutical/biotech companies.

Before Predictive Oncology

From 1981-2016 Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology. Dr. DeLucas received five degrees from UAB culminating in a Doctor of Optometry degree and a Ph.D. degree in Biochemistry. He also received honorary Doctor of Science degrees from The Ohio State University, Ferris State University, the State University of New York (SUNY), and the Illinois College of Optometry. He has published 164 peer-reviewed research articles in various scientific journals, co-authored and edited several books on protein crystal growth and membrane proteins and is a co-inventor on 43 patents involving protein crystal growth, novel biotechnologies and structure-based drug design. DeLucas was a payload specialist NASA astronaut and member of the 7-person crew of Space Shuttle Columbia for Mission “STS-50”, called the United States Microgravity Laboratory-1 (USML-1) Spacelab mission. Columbia launched on June 25, 1992, returning on July 9.  In 1994 and 1995, Dr. DeLucas served as the Chief Scientist for the International Space Station at NASA Headquarters in Washington, D.C. In 1999, Dr. DeLucas was recognized as one of the scientists who could shape the 21st century in an article published by “The Sunday Times” of London titled “The Brains Behind the 21st Century”.  In 2004, he was recognized as a Top Ten Finalist for the Entrepreneur of the Year award from the Birmingham Business Journal. 

“ Soluble Biotech is continually demonstrating to pharmaceutical and biotech companies the significant value of its novel HSC technology for optimizing protein therapeutic formulations to treat a variety of chronic and infectious diseases. ”

Education
  • Five degrees from Univ. of Alabama at Birmingham (UAB): B.S. Chemistry, M.S. Chemistry, B.S. Physiological Optics, O.D. Optometry, PhD Biochemistry

  • Published 164 peer-reviewed research articles in various scientific journals

  • 1993-2016: Director of the UAB Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology.

  • NASA Astronaut, flew on Columbia Space

  • 994-1995: Appointed Chief Scientist for the International Space Station at NASA HQ

    • TumorGenesis® Normal or Transformed Ovary and Fallopian Tube Media (Ince FOMI) (Liquid)

    CHIEF EXECUTIVE OFFICER
    Predictive Oncology
    At Predictive Oncology
    This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO.
    Before Predictive Oncology
    This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO.

    “ Eliminating cancer is our overall goal.  This is not an easy task.  We are working hard every day to make this happen, using our novel technology and talented team of employees. ”

     

     

    Education

    University of Southern California
    School of Business
    MBA, Finance

    University of Colorado Boulder
    BS, Accounting

    Richard Gabriel, BS, MBA

    SVP, RESEARCH & DEVELOPMENT
    Predictive Oncology
    Site Leader, TumorGenesis
    At Predictive Oncology
    My role at Predictive Oncology is to bring the business sense to managing Research and Development programs at all our companies. To seek new ways and opportunities to commercialize exciting new technologies that we have built, licensed, acquired, or are developing through our own research and development. The success of any company is to get the research off the bench and to the customers. That is what I do at POAI and help the other companies as well.
    Before Predictive Oncology
    Prior to starting his first company in 1984 and registering with the FDA a pilot plant facility to make pharmaceutical actives, Mr. Gabriel managed a $50 million product line for W.R. Grace, developed new marketing and sales strategies for Ventron a Division of Morton Thiokol, research work at Ashland Chemical for pressure sensitive adhesives and plant scale-up. Since then, he ran a genetics company, built three GMP/Research facilities, and helped 5 drugs reach their markets in AIDS and cancer. Real expertise in cGMP process scale-up and compliance. Completely understand the needs of an API manufacturing facility and build processes that are scalable, environmentally acceptable, and safe. 3 FDA inspections with no 483’s, ISO certification, DEA registration, DoD compliance, NCI contractor and inventor. Has also broad-based experience in start-up companies and how to make them operational and profitable. 7 years of Team set-up, R&D management, and implementation for 165-person (85 PhD’s and Engineers) company (Pharm-Eco) and lecturer on cGMP and Teams within the Pharmaceutical Industry.
    “ Patients are always first, is our driving force. Oncology is a tough space, and we are determined to bring the best validated science to help cancer patients and as our CEO says; “Eliminate Cancer”. You first must know your enemy before you can defeat them. That takes teamwork and a lot of smart hard-working people, our team members at POAI are up to the challenge. ”

     

     

    Education
    Suffolk University
    Executive MBA Program

    Ohio Dominican College
    BS, Chemistry

    Ohio State University
    Microbiology and Virology

    University of Cincinnati
    Associates Degree, Liberal Arts

    Mark A Collins, Ph.D

    SCIENTIFIC/CUSTOMER DEVELOPMENT
    Predictive Oncology
    Chief Technical Officer, Helomics
    At Predictive Oncology

    Mark is currently Chief Technical Officer at Predictive Oncology. Using the power of AI, Mark is responsible for leveraging Helomics’ vast repository of physical and digital tumor samples, to build multi-omic predictive models of tumor drug response and outcome. Such models can be applied to the discovery of new targeted therapies for cancer as well as used in clinical decision support to help oncologists individualize  treatment.

    Before Predictive Oncology

    Dr. Mark Collins embarked on a career in the pharmaceutical industry following his postdoctoral work. Pursuing a passion for both biology and computing, Mark has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the artificial intelligence (AI) machine learning (ML) and drug discovery space. Mark relocated to the USA in 2001 to work for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content cell analysis market, building, and commercializing several key informatics and bioinformatics products.

    Since leaving Thermo Fisher, Mark has focused on developing and commercializing informatics solutions for clinical and translational research, specifically in the specimen tracking, ‘omics data management and NGS analysis space, through key roles at BioFortis, Global Specimen Solutions and Genedata

    “ I have been pursuing a vision since the late 1990s that AI will help deliver better patient therapies. I firmly believe at POAI we will deliver on that vision. ”

    Education
    University of Surrey, UK
    Ph.D., Microbiology

    University of Wolverhampton, UK
    Undergraduate Degree, Applied Science

    Bob Myers

    CHIEF FINANCIAL OFFICER
    Predictive Oncology
    Site Leader, Skyline Medical
    At Predictive Oncology

    Executive officer, Compliance Officer, Corporate Secretary, and member of the Senior Leadership Team. Responsible for Finance, Administration, Human Resources, Investor Relations, and IT. Skyline Medical Site Leader.

    Before Predictive Oncology

    Numerous years as CEO/Controller consultant including medical devices companies. Executive positions with CES Computer Solutions, Computer Accomplishments, Hi-Tech Stationary & Printing, Capital Distributors Corp, International Creative Management American Express, Showtime Entertainment and public accounting with Laventhol & Horwath, CPA’s.

    “ It’s a privilege to work with a highly talented team to pursue oncology advances, while protecting and increasing shareholder value. ”

    Education

    Adelphi University
    MBA, Finance

    Hofstra University
    BBA, Public Accounting 

    J. Melville (“Mel”) Engle

    CHIEF EXECUTIVE OFFICER
    & CHAIRMAN OF THE BOARD
    Predictive Oncology
    At Predictive Oncology
    Mr. Engle became POAI’s CEO in 2021 and was appointed to the POAI Board of Directors in 2016. He was elected Chairman of the Board in 2020.
    Before Predictive Oncology
    Between 2012 and 2021, he was CEO of Engle Strategic Solutions, a consulting and coaching company focused on CEO issues. From 2009 to 2012, he was CEO and Chairman of Thermogenesis, a cell separation company. From 2002 to 2007, he was Regional Head/Director, North America at Merck Generics and CEO of Dey Laboratories, a respiratory company From 1996 to 2001, he was CEO and Chairman of Anika Therapeutics, an orthobiologics company From 1980 to 1995, he was with Allergan, Inc., an eye and skin care company, where he served as CFO, Managing Director (living in Toronto), and other positions with the firm

    “ Eliminating cancer is our overall goal.  This is not an easy task.  We are working hard every day to make this happen, using our novel technology and talented team of employees. ”

    Education

    University of Southern California
    School of Business
    MBA, Finance

    University of Colorado Boulder
    BS, Accounting